SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker, Stephan D. Wiviott, Itamar Raz, Kyungah Im, Erica L. Goodrich, Marc P. Bonaca, Ofri Mosenzon, Eri T. Kato, Avivit Cahn, Remo H. M. Furtado, Deepak L. Bahatt, Lawrence A. Leiter, Darren K. McGuire, John P. H. Wilding, Marc S. Sabatine (in Lancet 2019;393:31-39)
Entrevistada: Cristina Gavina
Entrevistador: Ricardo Fontes-Carvalho
Link: https://www.youtube.com/watch?v=IeUqwbhKVm0&list=PL-uOq5lzrAwa8yYWWoJ9RQphZyY3DVyEx∈dex=12
Conflicts of interestThe authors have no conflicts of interest to declare